印度批准AstraZeneca的 Trastuzumab Deruxtecan 用于治疗不同类型癌症的HER2-阳性固态肿瘤。 India approves AstraZeneca’s Trastuzumab Deruxtecan for HER2-positive solid tumors across cancer types.

AstraZeneca已经获得印度CDSCO的核准,将Trastuzumab Deruxtecan的使用范围扩大到非剖腹产或转移性HER2-呈阳性的固态肿瘤的成年病人,这些病人经过以前的治疗后选择的治疗途径有限。 AstraZeneca has received approval from India’s CDSCO to expand the use of Trastuzumab Deruxtecan for adult patients with unresectable or metastatic HER2-positive solid tumors who have limited treatment options after prior therapies. 这标志着印度批准的第一个也是唯一的肿瘤-不可知性抗体药物合体,允许根据基因标记而不是肿瘤位置进行多种癌症类型的治疗。 This marks the first and only tumor-agnostic antibody drug conjugate approved in India, allowing treatment across multiple cancer types based on a genetic marker rather than tumor location. 印度已经针对某些乳腺癌和胃癌批准使用该药物。 The drug is already approved for certain breast and gastric cancers in India. 2025年10月7日宣布的这项批准反映了在精确肿瘤学和AstraZeneca对公平获得创新癌症治疗的承诺方面取得的进展。 The approval, announced October 7, 2025, reflects progress in precision oncology and AstraZeneca’s commitment to equitable access to innovative cancer therapies.